Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease. Its mechanism is still not clear. Majority of research focused on the central nervous system (CNS) changes, while few studies emphasize on peripheral immune system modulation. Our study aimed to investigate the regulation of the peripheral immune system and its relationship to the severity of the disease after treatment in an AD model of APPswe/PSEN1dE9 transgenic (APP/PS1 Tg) mice. APP/PS1 Tg mice (8 months old) were treated with the ROCK-II inhibitor 1-(5-isoquinolinesulfonyl)-homo-piperazine (Fasudil) (intraperitoneal (i.p.) injections, 25 mg/kg/day), bone marrow stromal cells (BMSCs; caudal vein injections, 1 × 10
Recommended CitationYu, Jiezhong; Yan, Yuqing; Gu, Qingfang; Kumar, Gajendra; Yu, Hongqiang; Zhao, Yijin; Liu, Chunyun; Gao, Ye; Chai, Zhi; Chumber, Jasleen; Xiao, Bao-Guo; Zhang, Guang-Xian; Zhang, Han-Ting; Jiang, Yuqiang; and Ma, Cun-Gen, "Fasudil in Combination With Bone Marrow Stromal Cells (BMSCs) Attenuates Alzheimer's Disease-Related Changes Through the Regulation of the Peripheral Immune System." (2018). Department of Neurology Faculty Papers. Paper 161.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.